期刊文献+
共找到597篇文章
< 1 2 30 >
每页显示 20 50 100
Detection of Low Density Lipoprotein Receptor Related Protein Gene Polymorphism and Serum Lipid Levels in Renal Transplant Recipients
1
作者 Yuxin Wang Qingqin Li +4 位作者 Hequn Zou Yuanshan Lu Qinjun Xu Xiaodao Tang Dai Li 《器官移植内科学杂志》 2008年第4期170-175,共6页
关键词 肾移植术 低密度脂蛋白 聚合酶链反应 临床分析
下载PDF
Relationship between the low density lipoprotein receptor gene polymorphism and serum lipid levels in the Guangxi Bai Ku Yao population
2
作者 LONG Xing-jiang,YIN Rui-xing,LI Ke-la,LIU Wan-ying, ZHANG Lin,CAO Xiao-li,MIAO Lin,WU Dong-feng,ZENG Huan-yu,HU Xi-jiang (Department of Cardiology,Institute of Cardiovascular Diseases, The First Affiliated Hospital,Guangxi Medical University, Nanning 530021,China) 《岭南心血管病杂志》 2011年第S1期154-155,共2页
Objectives Bai Ku Yao(White-trousers Yaos)is a special branch of Yao minority in China.They are now living in both Lihu and Baxu villages,Nandan County, Guangxi,China.The population size is about 30,000.The special cu... Objectives Bai Ku Yao(White-trousers Yaos)is a special branch of Yao minority in China.They are now living in both Lihu and Baxu villages,Nandan County, Guangxi,China.The population size is about 30,000.The special customs and culture of Bai Ku Yao,including their special clothing,intra-ethnic marriages and alcohol intake are still completely conserved to the present day.In previous epidemiologic studies,we found that the serum lipid levels and the prevalence of hyperlipidaemia were lower in Bai Ku Yao than in Han Chinese from the same region.This ethnic difference in serum lipid profiles is still not well known.We hypothesized that there may be significant differences in some genetic polymorphismsssociation of low density lipoprotein receptor (LDL-R) genepolymorphism and several environmental factors with serum lipid levels in the Guangxi Bai Ku Yao and Han populations.Methods A total of 1024 subjects of Bai Ku Yao and 792 participants of Han Chinese were stud- ied by a stratified randomized cluster sampling.Epidemiological survey was carried out using internationally standardized methods.Information on demographics,socioeconomic status, and lifestyle factors was collected with standardized questionnaires. The height,weight,waist circumference,blood pressure, and serum total cholesterol(TC),triglyceride(TG), high-density lipoprotein cholesterol(HDL-C),low-density lipoprotein cholesterol(LDL-C),apolipoprotein(Apo) A1, and ApoB were measured.Body massindex(BMI,kg/m2) was calculated.Genotyping of the LDL-RAvaⅡwas performed by polymerse chain reaction and restriction fragment length polymorphism combined with gel electrophoresis,and then confirmed by direct sequencing.Results(l)The height,weight,serum TC,HDL-C,LDL-C,ApoAl levels and the ratio of ApoAl to ApoB were lower in Bai Ku Yao than in Han Chinese(P【0.01 for all),whereas the percentage of subjects who consumed alcohol or smoked cigarettes was higher in Bai Ku Yao than in Han Chinese(P【0.01 for each).(2) The frequency of A+ allele in Bai Ku Yao was 34.5%,and the frequencies of A-A-,A-A+ and A+A + genotypes were 42.6%,45.9%and 11.5%;respectively. The frequency of A+ allele in Han Chinese was 19.3%(P【0.001),and the frequencies of A-A-,A-A + and A+A+ genotypes were 64.9%,31.6%and 3.5%(P【0.001);respectively. The frequencies of A-A-,A-A+ and A+A+ genotypes in Bai Ku Yao were significant difference between males and females,between normal TC and high TC subgroup, and between normal LDL-C and high LDL-C subgroup (P【0.05 for all),whereas the frequencies of A- and A+ ? alleles in Han Chinese were significant difference between males and females(P【0.05).(3) Serum LDL-C levels in Bai Ku Yao were significant difference among the A-A-, A-A+ and A+A+ genotypes(P【0.05),the A+ carriers had higher serum LDL-C levels.Serum HDL-C levels in Han Chiese were significant difference among the A-A-,A-A + and A+A+ genotypes(P【0.01),the A+ carriers had higher serum HDL-C levels.(4) After adjusting other factors,the prevalence of LDL-C abnormality was still higher in Han Chiese than in Bai Ku Yao.The prevalence of TC abnormality in Han Chinese was almost twice high as in Bai Ku Yao. The age and diet were common risk factor for TC abnormality. No effect of AvaⅡgenotype or alcohol consumption on the TC abnormality was found,but the combination of geno-type and alcohol consumption can increase the prevalence of TC abnormality[Exp(B) =(1.154)].Age was negatively cor- related with TG level.Conclusions Serum TC and LDL-C levels were lower in Bai Ku Yao than in Han Chinese.There were significant differences in the AvaⅡallele and genotype frequencies between the he A+ carriers in Bai Ku Yao had higher serum LDL-C levels,whereas the A+ carriers in Han had higher serum HDL-C levels.Interactions between alcohol consumption or cigarette smoking and the LDL-R AvaⅡgenotype were also observed.The differences in the serum lipid profiles between the two ethnic groups might partly result from different genotypic frequency of LDL-R AvaⅡpolymorphism or differentgene-enviromental interactions.Bai Ku Yao and Han population,the frequency of A + allele was higher in Bai Ku Yao than in Han.T between the two ethnic groups.Therefore,the aim of the present study was to detect the 展开更多
关键词 LDL Relationship between the low density lipoprotein receptor gene polymorphism and serum lipid levels in the Guangxi Bai Ku Yao population gene
下载PDF
Improving a Patient’s CVD Risk Assessment—Updating the Interpretation of the Lipid Profile
3
作者 David S. Schade Allen Adolphe Robert Philip Eaton 《World Journal of Cardiovascular Diseases》 CAS 2024年第9期515-520,共6页
The lipid profile remains an important laboratory assessment to prevent cardiovascular disease. Interpretation of the non-fasting lipid profile has significantly changed based on new information concerning the pathoge... The lipid profile remains an important laboratory assessment to prevent cardiovascular disease. Interpretation of the non-fasting lipid profile has significantly changed based on new information concerning the pathogenesis of atherosclerosis. In particular, the assessment of risk from cholesterol containing particles following triglyceride metabolism (termed remnant cholesterol) can now be done from a lipid profile. In addition, non-HDL cholesterol as calculated from the lipid profile will provide a complete assessment of total circulating cholesterol containing particles. Furthermore, the formula for measurement of LDL cholesterol from a lipid profile has now been revised so that triglyceride levels exert less interference. Finally, the old concept that the “higher the HDL-c, the better” is no longer tenable. New data indicate that the optimal high density lipoprotein level is below 100 mg/dl for both male and female patients. Correct interpretation of the lipid profile will optimize anti-atherosclerotic therapy and reduce the number one cause of death in the United States. 展开更多
关键词 lipid Profile Atherosclerotic Risk Cardiovascular Disease High Density Lipoprotein low Density Lipoprotein
下载PDF
ASurvey on Treatment of Hyperlipidemia inPatients with Coronary Artery Disease 被引量:1
4
作者 Yang Zhijian(杨志健)\ Yang Bing(杨 兵) Zhu Tiebing(朱铁兵) Huang Jun(黄 峻) Wang Haiyan(王海燕) Cao Kejiang(曹克将)\ Zhang Fumin(张馥敏) Ma Wenzhu Department of Cardiology, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, P. R. China 《The Journal of Biomedical Research》 CAS 1999年第2期86-89,共4页
A retrospective analysis was made on the lipid level and management of those patients who experienced coronary angiography for suspected coronary artery disease and those who suffered from acute myocardial infarction ... A retrospective analysis was made on the lipid level and management of those patients who experienced coronary angiography for suspected coronary artery disease and those who suffered from acute myocardial infarction admitted to our department from 1994 to 1997. It revealed: ①Incidence of elevated serum lipids (especially total cholesterol) was higher in patients with CHD than those without CHD; ② No significant difference of serum lipids in patients with single or multi vessel disease was seen except higher serum lipids in patients with multi vessel disease; ③Management for elevated lipid in our cases was not active, even neglected in our clinic practice. Attention should be paid on these problems. 展开更多
关键词 survery HYPERlipidEMIA coronary artery disease lipid lowing
下载PDF
双模态成像仿生纳米粒对甲状腺髓样癌的声动力治疗
5
作者 朱炜薇 凡正超 +2 位作者 胥莹 夏纪筑 赵香芝 《中国组织工程研究》 CAS 北大核心 2025年第16期3410-3419,共10页
背景:声动力疗法作为一种新型抗肿瘤治疗手段具有非侵入性和时空可控性的特点,在甲状腺髓样癌无创性治疗中具有广阔的应用前景。目的:制备具有双模态成像能力的仿生癌细胞膜涂层脂质纳米粒,检测纳米粒的理化性质、靶向能力、成像效果、... 背景:声动力疗法作为一种新型抗肿瘤治疗手段具有非侵入性和时空可控性的特点,在甲状腺髓样癌无创性治疗中具有广阔的应用前景。目的:制备具有双模态成像能力的仿生癌细胞膜涂层脂质纳米粒,检测纳米粒的理化性质、靶向能力、成像效果、细胞毒性和抗迁移能力。方法:以二棕榈酰磷脂酰胆碱、二棕榈酰磷脂酰甘油、二硬脂酰磷脂酰乙醇胺-聚乙二醇2000、胆固醇、血卟啉单甲醚、全氟己烷为原料,通过薄膜水合-超声振荡法制备脂质纳米粒HP@LNP,其中血卟啉单甲醚装载于脂质纳米结构的疏水层,全氟己烷装载于脂质纳米结构的亲水核心层内;将甲状腺髓样癌细胞膜包覆于脂质纳米粒HP@LNP表面,构建具有主动靶向甲状腺髓样癌细胞能力的仿生脂质纳米粒MHP@LNP。表征纳米粒MHP@LNP的理化性质、靶向能力、免疫逃逸能力、成像效果、细胞毒性和抗迁移能力。结果与结论:①脂质纳米粒MHP@LNP呈现典型的核壳结构,粒径为131.06 nm,平均电位为-30.59 mV,凝胶电泳结果显示脂质纳米粒MHP@LNP与癌细胞膜蛋白图谱相符合,荧光共定位结果显示脂质纳米粒MHP@LNP与癌细胞膜的荧光信号显著重合。脂质纳米粒MHP@LNP纳米粒内血卟啉单甲醚的包封率为87.8%,载药率为14.6%。在低强度聚焦超声刺激下,脂质纳米粒MHP@LNP可发生相变产生微泡,在4 min时超声信号强度达到最大值。在激光照射下,脂质纳米粒MHP@LNP的光声信号强度与其质量浓度呈现线性相关。脂质纳米粒MHP@LNP具有同源细胞靶向能力和免疫逃逸能力。未经低强度聚焦超声照射前的脂质纳米粒MHP@LNP具有良好的生物相容性,而经低强度聚焦超声照射后产生具有细胞毒性的活性氧,有效杀伤甲状腺髓样癌细胞,并抑制甲状腺髓样癌细胞的迁移能力。②结果表明,脂质纳米粒MHP@LNP能够在超声和光声双模态成像引导下实现声动力治疗,用于治疗甲状腺髓样癌。 展开更多
关键词 脂质纳米粒 声动力疗法 低强度聚焦超声 声敏剂 活性氧 癌细胞膜 同源靶向 纳米医学 光声成像 双模态成像
下载PDF
Inflammation, lipid metabolism and cardiovascular risk in rheumatoid arthritis: A qualitative relationship? 被引量:4
6
作者 Carmen García-Gómez Maria Bianchi +4 位作者 Diana de la Fuente Lina Badimon Teresa Padró Emili Corbella Xavier Pintó 《World Journal of Orthopedics》 2014年第3期304-311,共8页
Life expectancy in patients with rheumatoid arthritis(RA)is reduced compared to the general population owing to an increase in cardiovascular diseases(CVD)not fully explained by traditional cardiovascular risk factors... Life expectancy in patients with rheumatoid arthritis(RA)is reduced compared to the general population owing to an increase in cardiovascular diseases(CVD)not fully explained by traditional cardiovascular risk factors.In recent years,interest has been focused on the alterations in lipid metabolism in relation to chronic inflammation as one of the possible mechanisms involvedin the pathogenesis of atherosclerosis of RA patients.Research regarding this issue has revealed quantitative alterations in lipoproteins during the acute-phase reaction,and has also demonstrated structural alterations in these lipoproteins which affect their functional abilities.Although many alterations in lipid metabolism have been described in this regard,these structural changes associated with inflammation are particularly important in high-density lipoproteins as they affect their cardioprotective functions.In this respect,excessive oxidation in low-density lipoprotein(LDL)and increased lipoprotein(a)with a predominance of smaller apolipoprotein(a)isoforms has also been reported.This article will discuss proinflammatory high-density lipoproteins(pi HDL),oxidized LDL and lipoprotein(a).Elevated concentrations of these lipoproteins with marked pro-atherogenic properties have been observed in RA patients,which could help to explain the increased cardiovascular risk of these patients. 展开更多
关键词 RHEUMATOID ARTHRITIS Cardiovascular disease LIPOPROTEINS PROINFLAMMATORY high-density LIPOPROTEINS Lipoprotein(a) Oxidized low-DENSITY LIPOPROTEINS lipid metabolism INFLAMMATION
下载PDF
Influences of blood lipids on the occurrence and prognosis of hemorrhagic transformation after acute cerebral infarction: a case-control study of 732 patients 被引量:64
7
作者 Gang Lv Guo-Qiang Wang +5 位作者 Zhen-Xi Xia Hai-Xia Wang Nan Liu Wei Wei Yong-Hua Huang Wei-Wei Zhang 《Military Medical Research》 SCIE CAS CSCD 2019年第3期189-200,共12页
Background: To study the influence of blood lipid levels on hemorrhagic transformation(HT) and prognosis after acute cerebral infarction(ACI).Methods: Patients with ACI within 72 h of symptoms onset between January 1 ... Background: To study the influence of blood lipid levels on hemorrhagic transformation(HT) and prognosis after acute cerebral infarction(ACI).Methods: Patients with ACI within 72 h of symptoms onset between January 1 st, 2015, and December 31 st, 2016, were retrospectively analyzed. Patients were divided into group A(without HT) and group B(HT). The outcomes were assessed after 3 months of disease onset using the modified Rankin Scale(m RS). An m RS score of 0–2 points indicated excellent prognosis, and an m RS score of 3–6 points indicated poor prognosis.Results: A total of 732 patients conformed to the inclusion criteria, including 628 in group A and 104 in group B. The incidence of HT was 14.2%, and the median onset time was 2 d(interquartile range, 1–7 d). The percentages of patients with large infarct size and cortex involvement in group B were 80.8% and 79.8%, respectively, which were both significantly higher than those in group A(28.7 and 33.4%, respectively). The incidence rate of atrial fibrillation(AF) in group B was significantly higher than that in group A(39.4% vs. 13.9%, P<0.001). The adjusted multivariate analysis results showed that large infarct size, cortex involvement and AF were independent risk factors of HT, while total cholesterol(TC) was a protective factor of HT(OR=0.359, 95% CI 0.136–0.944, P=0.038). With every 1 mmol/L reduction in normal TC levels, the risk of HT increased by 64.1%. The mortality and morbidity at 3 months in group B(21.2% and 76.7%, respectively) were both significantly higher than those in group A(8.0% and 42.8%, respectively). The adjusted multivariate analysis results showed that large infarct size(OR=12.178, 95% CI 5.390–27.516, P<0.001) was an independent risk factor of long-term unfavorable outcomes, whereas low-density lipoprotein cholesterol(LDL-C) was a protective factor(OR=0.538, 95% CI 0.300–0.964, P=0.037). With every 1 mmol/L reduction in normal LDL-C levels, the risk of an unfavorable outcome increased by 46.2%. Major therapies, including intravenous recombinant human tissue plasminogen activator(r TPA), intensive lipid-lowering statins and anti-platelets, were not significantly related to either HT or long-term, post-ACI poor prognosis.Conclusions: For patients with large infarct sizes, especially those with cortex involvement, AF, or lower levels of TC, the risk of HT might increase after ACI. The risk of a long-term unfavorable outcome in these patients might increase with a reduction in LDL-C. 展开更多
关键词 Acute cerebral infarction HEMORRHAGIC transformation Total cholesterol low-DENSITY LIPOPROTEIN Intensive lipid-lowERING STATINS ANTI-PLATELET Atrial fibrillation modified Rankin scale
下载PDF
Editorial on hemoglobin A1c, blood pressure, and lowdensity lipoprotein cholesterol goals in diabetics 被引量:2
8
作者 Wilbert S Aronow 《World Journal of Cardiology》 CAS 2013年第5期119-123,共5页
The American Diabetes Association (ADA) 2013 guidelines state that a reasonable hemoglobin A1c goal for many nonpregnant adults with diabetes is less than 7.0% a hemoglobin A1c level of less than 6.5% may be considere... The American Diabetes Association (ADA) 2013 guidelines state that a reasonable hemoglobin A1c goal for many nonpregnant adults with diabetes is less than 7.0% a hemoglobin A1c level of less than 6.5% may be considered in adults with short duration of diabetes, long life expectancy, and no significant cardiovascular disease if this can be achieved without significant hypoglycemia or other adverse effects of treatment. A hemoglobin A1c level less than 8.0% may be appropriate for patients with a history of severe hypoglycemia, limited life expectancy, advanced macrovascular and microvascular complications, extensive comorbidities, and long-standing diabetes in whom the hemoglobin A1c goal is difficult to attain despite multiple glucoselowering drugs including insulin. The ADA 2013 guidelines recommend that the systolic blood pressure in most diabetics with hypertension should be reduced to less than 140 mmHg. These guidelines also recommend use of an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker in the treatment of hypertension in diabetics unless they are pregnant. Diabetics at high risk for cardiovascular events should have theirserum low-density lipoprotein (LDL) cholesterol lowered to less than 70 mg/dL with statins. Lower-risk diabetics should have their serum LDL cholesterol reduced to less than 100 mg/dL. Combination therapy of a statin with either a fibrate or niacin has not been shown to provide additional cardiovascular benefit above statin therapy alone and is not recommended. Hypertriglyceridemia should be treated with dietary and lifestyle changes. Severe hypertriglyceridemia should be treated with drug therapy to reduce the risk of acute pancreatitis. 展开更多
关键词 Diabetes mellitus Blood pressure HEMOGLOBIN A1C Serum low-density LIPOPROTEIN cholesterol STATINS lipid-lowERING drugs
下载PDF
Protein in oxidized low density lipoprotein may cause injury to mitochondria of mouse peritoneal macrophages
9
作者 刘尚喜 周玫 +1 位作者 陈瑗 文维延 《Journal of Medical Colleges of PLA(China)》 CAS 1997年第4期265-268,272,共5页
Injury to mitochondria of macrophages caused by oxidized low density lipoprotein (Ox-LDL) and the role of lipid hydroperoxides (LOOH). lipid and protein in Ox-LDL on the injury were studied by measuring mito-chondrial... Injury to mitochondria of macrophages caused by oxidized low density lipoprotein (Ox-LDL) and the role of lipid hydroperoxides (LOOH). lipid and protein in Ox-LDL on the injury were studied by measuring mito-chondrial membrane potential (MMP) on ACAS570. The results showed that MMP decreased when macrophageswere treated by Ox-LDL. If LOOH in Ox-LDL was pre cleared by ebselen plus GSH. the decreased MMP could be recovered by about 20 %. Lipid moiety alone had no effect on IMP, but protein moiety could cause decrease ofMMP, the extent of the decrease was equivalent to that caused by Ox-LDL in which LOOH was pre-cleared by ebselen plus GSH. 展开更多
关键词 OXIDIZED low density LIPOPROTEIN lipid HYDROPEROXIDE APOB MACROPHAGES mitochondron mitochondrial membrane potential
下载PDF
The Impact of Statin Intolerance in Lipid Clinic Patients
10
作者 Kate Williams Vinita Mishra 《International Journal of Clinical Medicine》 2015年第5期314-321,共8页
Context: Cardiovascular disease is a very common and serious problem in the western world. Statin drug therapy is used in primary, secondary prevention and familial hypercholesterolemia. However, these are frequently ... Context: Cardiovascular disease is a very common and serious problem in the western world. Statin drug therapy is used in primary, secondary prevention and familial hypercholesterolemia. However, these are frequently associated with adverse effects, causing poor adherence and thus putting patients at risk for future cardiovascular events. Aim: The objective of this study was to review the statin intolerance in lipid patients and to assess the impact of alternative lipid lowering therapy on lipid parameters and cardiovascular outcome in statin intolerant patients. Methodology: 50 patients attending the out-patient lipid clinic of our hospital with statin intolerance were identified. Clinical data on the study patients were gathered retrospectively relating to statin intolerance and the clinical effectiveness of alternative lipid lowering therapy on lipid parameters and cardiovascular outcome. Results: Rosuvastatin was the most intolerable whereas pravastatin or fluvastatin was the most tolerable statin in our study patients. Myalgia was the commonly reported adverse effect of statin. The low dose statin monotherapy or combination of low dose statin and ezetemibe was the most tolerable alternative lipid lowering therapy in statin intolerant patients. After an average period of 10 months of initiation of alternative lipid lowering therapy;combination of low dose statin plus ezetimibe showed the largest reduction in serum total cholesterol and low-density lipoprotein (LDL) cholesterol levels. Conclusions: Pravastatin should be preferred in statin intolerant patients. A combination of low dose statin plus ezetimibe appeared to be the most tolerable and clinically effective therapy in statin intolerant patients. 展开更多
关键词 STATIN INTOLERANCE Alternative lipid lowering Therapy low-DENSITY LIPOPROTEIN (LDL) Total Cholesterol
下载PDF
氧化型低密度脂蛋白对2型糖尿病合并肺结核患者的风险评估价值
11
作者 桂静 王峰 +2 位作者 杨慧 蔡于茂 洪创跃 《实用医学杂志》 CAS 北大核心 2024年第14期1995-2002,共8页
目的探讨氧化型低密度脂蛋白(oxLDL)对2型糖尿病(T2DM)合并肺结核(PTB)患者的风险评估潜力。方法前瞻性纳入2022年6月至2023年6月门诊就诊的单纯高脂血症组病例60例、PTB组病例100例、T2DM组病例100例和T2DM合并PTB组病例100例,其中PTB... 目的探讨氧化型低密度脂蛋白(oxLDL)对2型糖尿病(T2DM)合并肺结核(PTB)患者的风险评估潜力。方法前瞻性纳入2022年6月至2023年6月门诊就诊的单纯高脂血症组病例60例、PTB组病例100例、T2DM组病例100例和T2DM合并PTB组病例100例,其中PTB组、T2DM组和T2DM合并PTB组再二次分组为血脂正常亚组40例和高脂血症亚组60例,共计360例为病例组;健康人群60例为对照组;入组年龄段为35~70岁。各组均采集静脉血,检测血液中的HbA1C、INS、FSG、TC、TG、HDL、LDL、ApoA I和Apo B,并采用ELISA法检测oxLDL,比较各组间的水平差异。应用多元logistic回归分析oxLDL水平与PTB和T2DM合并PTB的关联。结果T2DM高脂血症亚组的BMI、血糖、血脂和胰岛素抵抗等情况与T2DM合并PTB高脂血症亚组对比差异均无统计学意义(P>0.05);T2DM高脂血症亚组oxLDL水平高于对照组2倍以上,其血脂正常亚组的oxLDL水平显著高于对照组(P<0.05);T2DM合并PTB高脂血症亚组和单纯高脂血症组的oxLDL水平均显著高于对照组2倍以上,但与PTB高脂血症亚组相比,差异均无统计学意义(P>0.05)。相关性分析显示,T2DM高脂血症亚组和T2DM合并PTB高脂血症亚组的TG和LDL均与oxLDL呈显著正线性相关(R=0.352,P<0.05),PTB高脂血症亚组人群的CHOL和LDL均与oxLDL呈显著正线性相关(R=0.441,P<0.05);多元logistic回归分析显示oxLDL高于对照组2倍以上水平均是PTB和T2DM合并PTB的独立危险因素(均P<0.05)。结论显著升高的oxLDL水平可能是T2DM和PTB共病的危险因素,建议对oxLDL高于对照组2倍以上水平作为一个有临床意义的病理水平去进一步评估。 展开更多
关键词 2型糖尿病 肺结核 氧化型低密度脂蛋白 血脂
下载PDF
基于ox-LDL/LOX-1信号通路探讨脂质代谢紊乱促进肺癌进展中的机制 被引量:1
12
作者 吴阳 姚坚 陈金亮 《实用医学杂志》 CAS 北大核心 2024年第1期19-24,31,共7页
目的基于氧化低密度脂蛋白(ox-LDL)/人凝集素样氧化低密度脂蛋白受体1(LOX-1)信号通路探讨脂质代谢紊乱促进肺癌进展的机制。方法收集81个已鉴定的具有成对相邻非癌组织(离肿瘤至少5 cm)的肺腺癌组织,使用免疫组织化学检测LOX-1表达。... 目的基于氧化低密度脂蛋白(ox-LDL)/人凝集素样氧化低密度脂蛋白受体1(LOX-1)信号通路探讨脂质代谢紊乱促进肺癌进展的机制。方法收集81个已鉴定的具有成对相邻非癌组织(离肿瘤至少5 cm)的肺腺癌组织,使用免疫组织化学检测LOX-1表达。肺腺癌细胞系(A549、H1299细胞)中过表达LOX-1。用Transwell测定细胞侵袭能力。用不同浓度oxLDL处理细胞,并检测细胞中LOX-1表达情况。结果在包含原发性人肺癌和匹配的邻近非癌组织中,肿瘤中LOX-1染色比非癌组织样品明显增强(中值H分数99.4 vs.16.2,P<0.001)。高LOX-1表达与低生存显著相关(P<0.001)。与无淋巴结转移的患者相比,发生淋巴结转移患者的癌组织具有更高的LOX-1水平(中值H分数83.2 vs.121.1,P<0.01)。LOX-1过表达显著促进肺癌细胞的侵袭转移细胞数(P<0.01)。此外,LOX-1是ox-LDL诱导的肺癌细胞转移所必需的功能靶点。伊他替尼抑制LOX-1过表达的A549在体外的转移能力。结论LOX-1的表达随着oxLDL水平的升高而增加,并且LOX-1的表达上调促进了肺癌细胞的转移,其作用机制可能与激活Janus激酶/转录因子激活子(JAK1/STAT6)信号通路有关。 展开更多
关键词 氧化低密度脂蛋白 人凝集素样氧化低密度脂蛋白受体1 肺癌 脂质代谢
下载PDF
维生素D辅助低分子肝素钙对子痫前期患者机体凝血功能、脂质代谢及妊娠结局的影响 被引量:1
13
作者 陈素云 李卫文 +1 位作者 袁媛 郑建丽 《实用妇科内分泌电子杂志》 2024年第4期15-18,共4页
目的探讨分析维生素D辅助低分子肝素钙对子痫前期患者机体凝血功能、脂质代谢及妊娠结局的影响。方法选取52例子痫前期患者为研究对象,采用抛硬币法随机分为对照组和研究组,每组26例。对照组给予低分子肝素钙治疗,研究组在对照组基础上... 目的探讨分析维生素D辅助低分子肝素钙对子痫前期患者机体凝血功能、脂质代谢及妊娠结局的影响。方法选取52例子痫前期患者为研究对象,采用抛硬币法随机分为对照组和研究组,每组26例。对照组给予低分子肝素钙治疗,研究组在对照组基础上辅助应用维生素D,比较两组凝血功能、血脂指标以及妊娠结局。结果治疗前,两组纤维蛋白原(FIB)、活化部分凝血活酶时间(APTT)、凝血酶原时间(PT)、血清凝血酶时间(TT)水平比较,差异均无统计学意义(P>0.05);治疗后,两组FIB、APTT、PT、TT水平均优于治疗前,且研究组优于对照组(P<0.05);治疗前,两组总胆固醇(TC)、三酰甘油(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)水平比较,差异均无统计学意义(P>0.05);治疗后,研究组TC、TG、HDL-C、LDL-C水平均优于治疗前,且研究组优于对照组(P<0.05);两组HELLP综合征、肾功能不全发生率比较差异无统计学意义(P>0.05);研究组胎盘早剥发生率低于对照组,孕妇自觉症状改善率高于对照组(P<0.05)。结论子痫前期采用维生素D辅助低分子肝素钙治疗效果较好,可有效改善患者凝血功能与脂质代谢水平,减少不良妊娠结局发生率,值得临床推广与应用。 展开更多
关键词 子痫前期 维生素D 低分子肝素钙 凝血功能 脂质代谢 妊娠结局
下载PDF
补中温阳汤联合左甲状腺素钠在妊娠合并甲状腺功能减退症患者中的应用
14
作者 徐珊 段蓓 +2 位作者 张小菜 王敏 宋丽华 《国际医药卫生导报》 2024年第17期2926-2930,共5页
目的探讨中药配合甲状腺激素治疗对妊娠期合并甲状腺功能减退症(简称“甲减”)患者血脂调节效果,以及对母婴健康的影响。方法选取陕西中医药大学第二附属医院2022年7月至2023年6月就诊的98例妊娠期合并甲减患者进行随机对照试验,通过随... 目的探讨中药配合甲状腺激素治疗对妊娠期合并甲状腺功能减退症(简称“甲减”)患者血脂调节效果,以及对母婴健康的影响。方法选取陕西中医药大学第二附属医院2022年7月至2023年6月就诊的98例妊娠期合并甲减患者进行随机对照试验,通过随机数字表法分为对照组和联合组,每组各49例。对照组:年龄27~36(31.67±4.81)岁;入院体重指数(BMI)为(22.43±3.67)kg/m^(2);孕周为(19.09±1.34)周;予低剂量左甲状腺素钠片治疗,初始剂量为25μg/d,每隔4周进行复诊,如促甲状腺激素(TSH)水平未恢复正常,则根据患者耐受程度,依次将剂量调整为50~100μg/d,直到TSH水平恢复正常,共持续治疗12周。联合组:年龄29~39(32.07±5.13)岁;入院BMI为(22.19±3.28)kg/m^(2);孕周为(19.84±1.17)周;在对照组基础上联合补中温阳汤,水煎服,每日1剂,早、晚餐后分2次服用,连续服用12周。通过12周的持续治疗,观察分析两组患者的游离四碘甲状腺原氨酸(FT_(4))、TSH、甲状腺过氧化物酶自身抗体(TPOAb)阳性率、血清总胆固醇(TC)、甘油三酯(TAG)、低密度脂蛋白胆固醇(LDL-C)、母婴结局、新生儿发育水平以及临床总有效率。统计学方法采用t检验、χ^(2)检验。结果联合组临床总有效率高于对照组[85.71%(42/49)比67.35%(33/49)],差异有统计学意义(χ^(2)=4.60,P<0.05)。分娩后,联合组TSH、TPOAb水平、TPOAb阳性率均低于对照组[(1.97±0.46)IU/ml比(2.87±0.62)IU/ml、(8.12±1.47)IU/ml比(10.96±1.82)IU/ml、6.12%(3/49)比20.41%(10/49)],差异均有统计学意义(t=8.16、8.50,χ^(2)=4.35,均P<0.05);联合组血脂水平各项指标均低于对照组,差异均有统计学意义(均P<0.05)。联合组新生儿出生3个月后智力发育指数(MDI)、运动发育指数(PDI)评分均高于对照组[(86.94±5.86)分比(80.27±5.14)分、(85.72±5.15)分比(80.98±5.23)分],差异均有统计学意义(t=5.99、4.52,均P<0.05)。两组不良母婴结局发生率比较[4.08%(2/49)比16.33%(8/49)],差异有统计学意义(χ^(2)=4.01,P<0.05)。结论采用补中温阳汤联合低剂量左甲状腺素钠片治疗妊娠合并甲减患者,可有效改善患者甲状腺功能,降低血脂水平,优化母婴结局,提升新生儿发育水平。 展开更多
关键词 甲状腺功能减退症 妊娠期 补中温阳汤 低剂量左甲状腺素钠片 血脂水平 母婴结局
下载PDF
低温对合作猪脂肪组织形态、脂代谢相关基因表达和酶活性及AMPK/PGC-1α通路的影响
15
作者 李瑶 贾蕊 +6 位作者 李杰 滚双宝 杨巧丽 王龙龙 张鹏霞 高小莉 黄晓宇 《畜牧兽医学报》 CAS CSCD 北大核心 2024年第8期3418-3426,共9页
旨在探究低温对合作猪脂肪组织形态、脂代谢相关基因表达和酶活性及AMPK/PGC-1α通路的影响。本研究选择75日龄体重相近、健康状况良好的合作猪10头,常温饲养7 d后随机分为对照组((23±2)℃)和低温组((-15±2)℃),每组5头,试验... 旨在探究低温对合作猪脂肪组织形态、脂代谢相关基因表达和酶活性及AMPK/PGC-1α通路的影响。本研究选择75日龄体重相近、健康状况良好的合作猪10头,常温饲养7 d后随机分为对照组((23±2)℃)和低温组((-15±2)℃),每组5头,试验期15 d。试验结束后采集合作猪腋下和腹股沟脂肪组织,采用HE染色观察脂肪组织形态;ELISA法检测脂代谢相关酶活性;荧光定量PCR法检测脂肪棕色化产热基因和脂代谢相关基因的表达;Western blot检测AMPK/PGC-1α通路蛋白的表达。结果发现:与对照组相比,低温处理后合作猪腋下脂肪和腹股沟脂肪呈现褐色化改变,脂肪细胞数量变多且横截面积减小;腋下和腹股沟脂肪中LPL活性,IL-6 mRNA表达量及AMPK、P-AMPK和PGC-1α蛋白表达量极显著增加(P<0.01),LEP mRNA表达量及FAS活性极显著降低(P<0.01);腋下脂肪中UCP3、HSP 70 mRNA表达量显著增加(P<0.05),PPARγmRNA表达量显著降低(P<0.05),AMPK及TNF-αmRNA表达量极显著增加(P<0.01);腹股沟脂肪中AMPK及TNF-αmRNA表达量显著增加(P<0.05),UCP 3及HSP 70 mRNA表达量极显著增加(P<0.01),PPARγmRNA表达量极显著降低(P<0.01);低温处理后合作猪腹股沟脂肪中PGC-1α、ADPN、FAT mRNA表达量和HSL活性极显著增加(P<0.01),但在腋下脂肪中变化不显著(P>0.05)。综上,低温下合作猪腋下脂肪和腹股沟脂肪发生褐色化改变,且脂肪细胞数量增多,面积减小,机体产热增加,脂代谢关键基因LEP、ADPN、PPARγ、FAT及AMPK/PGC-1α通路可能参与机体脂质代谢。 展开更多
关键词 低温 脂肪组织 脂代谢 AMPK/PGC-1α
下载PDF
中国血脂管理指南(基层版2024年) 被引量:8
16
作者 中国血脂管理指南修订联合专家委员会 王增武 +3 位作者 李建军 赵水平 高润霖 郭远林 《中国循环杂志》 CSCD 北大核心 2024年第4期313-321,共9页
低密度脂蛋白胆固醇(LDL-C)是动脉粥样硬化性心血管疾病(ASCVD)的致病性危险因素。近几十年来,中国人群的血脂异常患病率不断升高,血脂管理刻不容缓,在基层开展血脂规范管理尤为重要。《中国血脂管理指南(基层版2024年)》简明地推荐LDL-... 低密度脂蛋白胆固醇(LDL-C)是动脉粥样硬化性心血管疾病(ASCVD)的致病性危险因素。近几十年来,中国人群的血脂异常患病率不断升高,血脂管理刻不容缓,在基层开展血脂规范管理尤为重要。《中国血脂管理指南(基层版2024年)》简明地推荐LDL-C作为血脂干预的首要靶点,以ASCVD危险分层确定其目标值;推荐在生活方式干预的基础上,以中等强度他汀类药物作为起始药物治疗,必要时联用胆固醇吸收抑制剂和(或)前蛋白转化酶枯草溶菌素9抑制剂的达标策略;并就常见特殊人群的血脂管理策略进行了推荐。本指南旨在为基层医师开展血脂管理提供指导,全面提升基层医师的血脂管理水平,推进ASCVD的一级和二级预防工作。 展开更多
关键词 动脉粥样硬化 心血管疾病 血脂管理 低密度脂蛋白胆固醇 基层
下载PDF
中国缺血性卒中及短暂性脑缺血发作患者血脂长期管理科学声明
17
作者 中国卒中学会医疗质量管理与促进分会 《中国缺血性卒中及短暂性脑缺血发作患者血脂长期管理科学声明》编写组 +2 位作者 王拥军 许杰 李子孝 《中国卒中杂志》 北大核心 2024年第4期440-451,共12页
中国缺血性卒中(ischemic stroke,IS)及TIA疾病负担沉重。LDL-C水平升高是卒中复发的独立危险因素,积极评估患者LDL-C不达标的原因,制订进一步治疗策略、监测频率以提高达标率具有重要临床意义。为加强医务工作者对IS及TIA疾病长期管理... 中国缺血性卒中(ischemic stroke,IS)及TIA疾病负担沉重。LDL-C水平升高是卒中复发的独立危险因素,积极评估患者LDL-C不达标的原因,制订进一步治疗策略、监测频率以提高达标率具有重要临床意义。为加强医务工作者对IS及TIA疾病长期管理及监测的认识,规范长期血脂管理临床实践,中国卒中学会医疗质量管理与促进分会组织相关脑血管病临床医学专家,基于循证证据和临床实践、经多轮专家意见收集和研讨,拟定本科学声明。本科学声明对IS及TIA患者长期血脂管理、长期血脂监测及重点患者血脂管理等方面进行了阐述,以期为提升IS及TIA患者的长期血脂管理临床规范提供参考。 展开更多
关键词 缺血性卒中 短暂性脑缺血发作 低密度脂蛋白胆固醇 血脂管理 科学声明
下载PDF
中国血脂管理指南(基层版2024年) 被引量:7
18
作者 中国血脂管理指南修订联合专家委员会 王增武 +3 位作者 李建军 赵水平 高润霖 郭远林 《中国全科医学》 CAS 北大核心 2024年第20期2429-2436,共8页
低密度脂蛋白胆固醇(LDL-C)是动脉粥样硬化性心血管疾病(ASCVD)的致病性危险因素。近几十年来,中国人群的血脂异常患病率不断升高,血脂管理刻不容缓,在基层开展血脂规范管理尤为重要。《中国血脂管理指南(基层版2024年)》简明地推荐LDL-... 低密度脂蛋白胆固醇(LDL-C)是动脉粥样硬化性心血管疾病(ASCVD)的致病性危险因素。近几十年来,中国人群的血脂异常患病率不断升高,血脂管理刻不容缓,在基层开展血脂规范管理尤为重要。《中国血脂管理指南(基层版2024年)》简明地推荐LDL-C作为血脂干预的首要靶点,以ASCVD危险分层确定其目标值;推荐在生活方式干预的基础上,以中等强度他汀类药物作为起始药物治疗,必要时联用胆固醇吸收抑制剂或/和前蛋白转化酶枯草溶菌素9抑制剂的达标策略;并就常见特殊人群的血脂管理策略进行了推荐。本指南旨在为基层医生开展血脂管理提供指导,全面提升基层医生的血脂管理水平,推进ASCVD的一级和二级预防工作。 展开更多
关键词 动脉粥样硬化 心血管疾病 血脂管理 低密度脂蛋白胆固醇 基层
下载PDF
隔药饼灸对动脉粥样硬化兔血清Ox-LDL、IFN-γ表达的影响 被引量:1
19
作者 易洪芬 陈昕羽 +4 位作者 彭涵 肖孟霞 欧阳里知 刘红华 刘迈兰 《湖南中医药大学学报》 CAS 2024年第9期1614-1619,共6页
目的 观察隔药饼灸对动脉粥样硬化(atherosclerosis,AS)兔血清氧化低密度脂蛋白(oxidized low-density lipoprotein,Ox-LDL)、干扰素(interferon-γ,IFN-γ)的影响,探讨隔药饼灸抗AS的作用机制。方法 将18只新西兰兔随机分为正常组、模... 目的 观察隔药饼灸对动脉粥样硬化(atherosclerosis,AS)兔血清氧化低密度脂蛋白(oxidized low-density lipoprotein,Ox-LDL)、干扰素(interferon-γ,IFN-γ)的影响,探讨隔药饼灸抗AS的作用机制。方法 将18只新西兰兔随机分为正常组、模型组、隔药饼灸组,每组6只。正常组给予普通饲料喂养,其余2组给予高脂饲料喂养,其中隔药饼灸组边造模边干预:2组穴位(巨阙、天枢、丰隆;心俞、肝俞、脾俞)交替行隔药饼灸干预,每穴灸4壮,每日1次,干预12周。HE染色观察主动脉组织病理变化,比色法检测总胆固醇(total cholesterol,TC)、甘油三酯(triglyceride,TG)、低密度脂蛋白胆固醇(low density liporotein cholesterol,LDL-C)、高密度脂蛋白胆固醇(high density lipoprotein cholesterol,HDL-C)含量,ELISA法检测Ox-LDL、IFN-γ含量。结果 与正常组比,模型组主动脉内皮明显增厚,平滑肌排列絮乱,泡沫细胞大量聚集,血清TC、TG、LDL-C、Ox-LDL、IFN-γ含量均显著升高(P<0.05,P<0.001),HDL-C含量显著下降(P<0.001)。与模型组比,隔药饼灸组主动脉内皮结构完整,平滑肌排列整齐,少见泡沫细胞,血清TC、TG、LDL-C、ox-LDL、IFN-γ含量均显著下降(P<0.05,P<0.01,P<0.001),HDL-C含量明显升高(P<0.05)。结论 隔药饼灸可能通过降低AS兔血清Ox-LDL、IFN-γ含量,减少巨噬细胞脂质摄取,抑制泡沫细胞形成,发挥抗AS的作用。 展开更多
关键词 动脉粥样硬化 隔药饼灸 氧化低密度脂蛋白 干扰素-γ 泡沫细胞 脂质
下载PDF
急性冠脉综合征患者PCI术后皮下注射依洛尤单抗的降脂效果及安全性观察
20
作者 孙玉宇 李丹妮 +1 位作者 夏林莺 金萍 《山东医药》 CAS 2024年第23期31-35,共5页
目的观察急性冠脉综合征(ACS)患者经皮冠状动脉介入治疗(PCI)术后皮下注射依洛尤单抗的降脂效果及安全性。方法选择行PCI手术的ACS患者145例,随机分为观察组73例、对照组72例。对照组术后按照ACS围手术期用药指南给予常规剂量他汀类药... 目的观察急性冠脉综合征(ACS)患者经皮冠状动脉介入治疗(PCI)术后皮下注射依洛尤单抗的降脂效果及安全性。方法选择行PCI手术的ACS患者145例,随机分为观察组73例、对照组72例。对照组术后按照ACS围手术期用药指南给予常规剂量他汀类药物治疗,观察组在对照组基础上每次皮下注射依洛尤单抗140 mg,2周1次,两组均治疗1个月。记录两组治疗前后血脂相关指标,包括总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、载脂蛋白B(ApoB)、脂蛋白(a)[Lp(a)]、载脂蛋白A1(ApoA1)、ApoB/ApoA1及LDL-C<1.8 mmol/L、LDL-C<1.4 mmol/L的比例,以及两组治疗后LDL-C较基线下降>50%且<1.4 mmol/L的比例。记录两组用药安全性相关指标,包括治疗前后的空腹血糖(FPG)、丙氨酸氨基转移酶(ALT)、肌酐(Cre),以及药物不良反应及主要不良心血管事件(MACE)发生情况。结果与治疗前比较,两组治疗后LDL-C<1.8 mmol/L及<1.4 mmol/L的比例均升高,且观察组较对照组升高更明显(P均<0.05)。观察组治疗后LDL-C较基线下降>50%且<1.4 mmol/L的比例高于对照组(P<0.05)。与治疗前比较,两组治疗后TC、TG、LDL-C、Lp(a)、ApoB、ApoB/ApoA1均降低,ApoA1均升高,且观察组较对照组治疗后变化更明显(P均<0.05)。两组治疗前后FPG、ALT及Cre比较差异均无统计学意义(P均>0.05)。观察组和对照组均发生肌痛1例,分别发生MACE 0、1例,两组比较P均>0.05。结论ACS患者PCI术后皮下注射依洛尤单抗有助于降低血脂水平,且安全性较高。 展开更多
关键词 依洛尤单抗 急性冠脉综合征 经皮冠状动脉介入治疗 血脂 低密度脂蛋白胆固醇
下载PDF
上一页 1 2 30 下一页 到第
使用帮助 返回顶部